Skip to main content
. Author manuscript; available in PMC: 2012 Dec 14.
Published in final edited form as: Nature. 2012 Apr 29;486(7402):266–270. doi: 10.1038/nature11114

Figure 3. USP9X loss promotes PDA.

Figure 3

a–c, Decreased USP9X expression correlates with shortened survival in Australian post-surgical cohort (a) (8.7 vs. 18.4 months, p=0.0076; log-rank test), increased metastatic burden in American autopsy series (b) (54% vs. 19%, p=0.0212; Fisher’s exact test), and diminished survival in German post-surgical cohort (c) (11.1 vs. 16.1 months, p=0.037; log-rank test). d, Trichostatin A (TSA, Red) and 5-Aza-2′-deoxycytidine (AZA, Blue) modestly increase USP9X mRNA expression. The mean and s.e.m. of one representative experiment performed in triplicate are shown. e, Usp9x deletion promotes mPanIN progression in KCU mice (p<0.0001; Fisher’s exact test). f, Representative normal pancreas (CU), mPanIN1 (KC), mPanIN3 (KCU) and microinvasive mPDA (KCU, arrow, circled). Scale bar: 100μm.